This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Plasma Levels of GDF-9 and GDF-15 in Patients With Polycystic Ovary Syndrome.

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2012 by Ankara Education and Research Hospital.
Recruitment status was:  Active, not recruiting
Information provided by:
Ankara Education and Research Hospital Identifier:
First received: July 17, 2012
Last updated: July 18, 2012
Last verified: July 2012
The purpose of this study is to determine the plasma levels of GDF-9 and GDF-15, and their association with bone and cardiovascular parameters in patients with Polycystic Ovary Syndrome.

Polycystic Ovary Syndrome

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional

Resource links provided by NLM:

Further study details as provided by Ankara Education and Research Hospital:

Primary Outcome Measures:
  • The association of GDF 9 AND GDF 15 with bone and cardiovascular parameters in women with polycystic ovary syndrome

Polycystic Ovary Syndrome
Idiopathic hirsutism


Ages Eligible for Study:   25 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Sampling Method:   Probability Sample
Study Population
Hospital Endocrinology Outpatient Clinic

Inclusion Criteria:

  • Female patients at ages 25-35 diagnosed with polycystic ovarian syndrome and idiopathic hirsutism

Exclusion Criteria:

  • acute infectious disease, a thyroid, pituitary, nutritional, inflammatory, hepatic, renal, or neoplastic disorder; history of cardiovascular disease or pulmonary embolism; a family history of coronary artery disease; smoking history; hypertension; diabetes mellitus; use of oral contraceptives, anti-androgens and drugs known to interfere with cytokine release, such as corticosteroids, immunosuppressors, or nonsteroidal antiinflammatory drugs.

any medication known to affect hormonal or metabolic parameters.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01644305

Ankara Education and Research Hospital
Ankara, Turkey, 06340
Sponsors and Collaborators
Ankara Education and Research Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT01644305     History of Changes
Other Study ID Numbers: 3849
Study First Received: July 17, 2012
Last Updated: July 18, 2012

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Pathologic Processes
Ovarian Cysts
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases processed this record on September 21, 2017